In brief, it appears that combinatorial unimolecular therapies, which incorporate GLP‐1 receptor benefits together with the metabolic advantages of other related gastrointestinal tract‐derived hormones, have unmistakeable therapeutic potential for obesity, diabetes and beyond. This evidence concerns the gene GLP1R and obesity disorder.